A 62-year-old man with long-standing diabetic nephropathy is receiving thrice-weekly haemodialysis. During follow-up, he complains of increasing diffuse bone aches and proximal muscle discomfort. His recent laboratory investigations show:
- Adjusted serum calcium: 2.16 mmol/L (low)
- Serum phosphate: 2.0 mmol/L (raised)
- Parathyroid hormone (PTH): 82 pmol/L (markedly raised)
- Alkaline phosphatase: 270 U/L (raised)
He is compliant with dietary phosphate restriction and is already prescribed a phosphate-binding agent.
Which of the following is the most appropriate additional therapy to control his underlying problem?
A. Alfacalcidol
B. Colecalciferol
C. Cinacalcet hydrochloride
D. Ergocalciferol
E. Lanthanum carbonate
Answer
Alfacalcidol
Detailed discussion for MRCP
This patient with end-stage renal disease (ESRD) has classical biochemical and clinical features of secondary hyperparathyroidism, part of the broader entity known as chronic kidney disease–mineral and bone disorder (CKD-MBD). The hallmark abnormalities include hypocalcaemia, hyperphosphataemia, markedly elevated PTH, raised alkaline phosphatase, and bone pain suggesting high-turnover bone disease (osteitis fibrosa cystica).
The central pathophysiological defect in advanced CKD is failure of the kidneys to perform 1-α hydroxylation of vitamin D, which normally converts 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D (calcitriol). Loss of active vitamin D leads to reduced intestinal calcium absorption, hypocalcaemia, and loss of negative feedback on the parathyroid glands, resulting in secondary hyperparathyroidism.
Alfacalcidol is 1-α-hydroxyvitamin D₃. It requires only hepatic activation and bypasses the renal 1-α hydroxylase step, making it ideal in ESRD. It suppresses PTH secretion, improves calcium absorption, and reduces bone turnover. This makes it the correct first-line pharmacological addition in a dialysis patient with uncontrolled secondary hyperparathyroidism.
Cholecalciferol (vitamin D₃) and ergocalciferol (vitamin D₂) are inactive precursors and require both liver and kidney activation. They are useful in early CKD (stages 1–3) but are ineffective in ESRD. Cinacalcet, a calcimimetic, lowers PTH by increasing calcium-sensing receptor sensitivity but is typically reserved for patients with persistent hyperparathyroidism despite optimal phosphate control and active vitamin D therapy, or when hypercalcaemia limits vitamin D use. Lanthanum carbonate is a non-calcium phosphate binder and does not directly suppress PTH.
For MRCP, it is essential to remember that treatment choice depends on CKD stage, calcium level, phosphate level, and PTH trend rather than a single value. Over-suppression of PTH risks adynamic bone disease, while poor control increases fracture risk and vascular calcification.
Cheat sheet (exam-focused)
- CKD → ↓ phosphate excretion → hyperphosphataemia
- CKD → ↓ 1-α hydroxylase → ↓ active vitamin D
- ↓ Vitamin D + ↑ phosphate → hypocalcaemia
- Hypocalcaemia + hyperphosphataemia → secondary hyperparathyroidism
- Raised ALP = high bone turnover
- ESRD treatment of secondary hyperparathyroidism: active vitamin D (alfacalcidol/calcitriol)
- Native vitamin D (D₂/D₃) only works in early CKD
- Cinacalcet = second-line or add-on therapy
- Aim: control calcium, phosphate, PTH and prevent fractures & vascular calcification
Flash cards
Q1: Why does CKD cause secondary hyperparathyroidism?
A: Reduced phosphate excretion and impaired vitamin D activation cause hypocalcaemia, stimulating PTH.
Explanation: Loss of renal 1-α hydroxylase is central.
Q2: Which enzyme is deficient in ESRD affecting vitamin D metabolism?
A: Renal 1-α hydroxylase.
Explanation: Prevents formation of calcitriol.
Q3: Why is alkaline phosphatase raised in secondary hyperparathyroidism?
A: Reflects increased osteoblastic activity from high bone turnover.
Explanation: Marker of osteitis fibrosa.
Q4: Best vitamin D preparation in ESRD?
A: Alfacalcidol.
Explanation: Does not require renal activation.
Q5: Role of phosphate binders in CKD?
A: Reduce intestinal phosphate absorption.
Explanation: Prevents hyperphosphataemia-driven PTH rise.
Q6: When is cholecalciferol appropriate in CKD?
A: Early CKD (stages 1–3).
Explanation: Requires renal activation.
Q7: Mechanism of cinacalcet?
A: Increases sensitivity of Ca-sensing receptors on parathyroid cells.
Explanation: Suppresses PTH secretion.
Q8: Bone disease seen in severe secondary hyperparathyroidism?
A: Osteitis fibrosa cystica.
Explanation: High-turnover bone disease.
Q9: Major long-term complication of uncontrolled CKD-MBD?
A: Vascular and soft-tissue calcification.
Explanation: Due to high Ca-phosphate product.
Q10: Why avoid excessive calcium supplementation?
A: Risk of hypercalcaemia and vascular calcification.
Explanation: Especially in dialysis patients.
Q11: Which lab parameter best reflects PTH activity on bone?
A: Alkaline phosphatase.
Explanation: Marker of bone turnover.
Q12: Indication for parathyroidectomy in CKD?
A: Refractory secondary hyperparathyroidism.
Explanation: When medical therapy fails.
Q13: Target of therapy in CKD-MBD?
A: Calcium, phosphate, and PTH control.
Explanation: Prevent bone and CV complications.
Q14: Why does hyperphosphataemia worsen hypocalcaemia?
A: Phosphate binds calcium.
Explanation: Reduces free serum calcium.
Q15: What happens if PTH is over-suppressed?
A: Adynamic bone disease.
Explanation: Low bone turnover, fracture risk.
Q16: Which CKD stage typically needs active vitamin D?
A: Stages 4–5.
Explanation: Renal activation lost.
Q17: Which symptom suggests renal osteodystrophy?
A: Diffuse bone pain.
Explanation: Reflects skeletal involvement.
Q18: Why is ESRD associated with muscle weakness?
A: Hypocalcaemia and vitamin D deficiency.
Explanation: Impaired neuromuscular function.
Q19: Which hormone primarily drives bone resorption here?
A: Parathyroid hormone.
Explanation: Excess PTH increases osteoclast activity.
Q20: Best initial pharmacological step after phosphate control?
A: Active vitamin D analogue.
Explanation: Addresses core pathophysiology.
MCQs to test yourself
- In ESRD, secondary hyperparathyroidism is primarily caused by:
A. Reduced intestinal calcium absorption due to diarrhoea
B. Failure of renal phosphate excretion
C. Increased calcitonin secretion
D. Excess dietary calcium
E. Increased vitamin D synthesis
Answer: B – phosphate retention and vitamin D deficiency drive PTH rise. - Which vitamin D preparation does not require renal activation?
A. Ergocalciferol
B. Cholecalciferol
C. Calcitriol
D. Alfacalcidol
E. 25-hydroxyvitamin D
Answer: D – only liver activation required. - Raised alkaline phosphatase in CKD reflects:
A. Liver failure
B. Reduced bone formation
C. High bone turnover
D. Aluminium toxicity
E. Vitamin B deficiency
Answer: C – marker of osteoblastic activity. - Which of the following is false regarding cinacalcet?
A. It lowers PTH
B. It increases calcium-sensing receptor sensitivity
C. It is first-line in all CKD patients
D. It can cause hypocalcaemia
E. It is useful when vitamin D causes hypercalcaemia
Answer: C – not first-line. - Native vitamin D is most effective in:
A. CKD stage 5
B. Dialysis patients
C. Post-transplant patients only
D. CKD stages 1–3
E. Anuric patients
Answer: D – requires renal activation. - Which complication is most closely linked to high Ca-phosphate product?
A. Anaemia
B. Vascular calcification
C. Hyperkalaemia
D. Metabolic acidosis
E. Amyloidosis
Answer: B – major cardiovascular risk. - Which lab abnormality best predicts bone pain in CKD-MBD?
A. Raised urea
B. Low albumin
C. High ALP
D. Low bicarbonate
E. High potassium
Answer: C – reflects bone turnover. - Which statement is false about secondary hyperparathyroidism?
A. PTH is elevated
B. Bone resorption increases
C. Calcium is usually high
D. Phosphate is elevated
E. Vitamin D is reduced
Answer: C – calcium is usually low or low-normal. - The main action of PTH on bone is:
A. Inhibition of osteoclasts
B. Increased bone mineralisation
C. Increased osteoclast-mediated resorption
D. Reduced alkaline phosphatase
E. Increased calcitonin secretion
Answer: C – causes bone loss. - Which treatment directly corrects impaired vitamin D activation?
A. Calcium carbonate
B. Sevelamer
C. Alfacalcidol
D. Lanthanum
E. Sodium bicarbonate
Answer: C. - In CKD-MBD, muscle pain is mainly due to:
A. Anaemia
B. Hypocalcaemia
C. Hyperkalaemia
D. Acidosis
E. Amyloid deposition
Answer: B. - Which of the following is false regarding phosphate binders?
A. Reduce dietary phosphate absorption
B. May cause hypercalcaemia
C. Improve renal vitamin D activation
D. Lower PTH indirectly
E. Reduce vascular calcification risk
Answer: C – they do not affect vitamin D activation. - Severe secondary hyperparathyroidism can cause:
A. Brown tumours
B. Paget disease
C. Osteoporosis only
D. Rickets
E. Osteomalacia alone
Answer: A – classic complication. - Optimal management goal in CKD-MBD includes all except:
A. Normal calcium
B. Normal phosphate
C. Suppressed PTH to zero
D. Prevention of fractures
E. Prevention of vascular calcification
Answer: C – over-suppression is harmful. - Which hormone normally suppresses PTH secretion?
A. Aldosterone
B. Calcitriol
C. Renin
D. Erythropoietin
E. Cortisol
Answer: B. - Which finding suggests high-turnover bone disease?
A. Low ALP
B. Low PTH
C. High ALP
D. Normal phosphate
E. Normal calcium
Answer: C. - Which is the earliest biochemical change in CKD-MBD?
A. Hypocalcaemia
B. Hyperphosphataemia
C. Raised ALP
D. Raised PTH
E. Bone pain
Answer: D – compensatory rise in PTH occurs early. - Which CKD-MBD treatment reduces cardiovascular mortality?
A. Aluminium binders
B. Untreated hyperphosphataemia
C. Phosphate control
D. High calcium intake
E. No vitamin D therapy
Answer: C – phosphate control reduces calcification. - Which statement is false about alfacalcidol?
A. Suppresses PTH
B. Increases calcium absorption
C. Requires renal activation
D. Useful in dialysis patients
E. Risk of hypercalcaemia exists
Answer: C – does not require renal activation. - The most appropriate next step when PTH remains high despite alfacalcidol is:
A. Stop vitamin D
B. Add cinacalcet
C. Stop phosphate binders
D. Give cholecalciferol
E. Ignore PTH
Answer: B – add calcimimetic if needed.
Summary for quick exam revision
Secondary hyperparathyroidism in chronic kidney disease results from phosphate retention and loss of renal 1-α hydroxylation of vitamin D, leading to hypocalcaemia, elevated PTH, and high-turnover bone disease. Patients often present with bone pain, myalgia, and raised alkaline phosphatase. Management aims to normalise calcium and phosphate levels, suppress excessive PTH, and prevent fractures and vascular calcification. Dietary phosphate restriction and phosphate binders are first-line measures. In advanced CKD and dialysis patients, native vitamin D preparations are ineffective because renal activation is lost. Active vitamin D analogues such as alfacalcidol or calcitriol are therefore first-line pharmacological therapy. Cinacalcet is reserved for refractory cases or when hypercalcaemia limits vitamin D use. Over-suppression of PTH should be avoided to prevent adynamic bone disease.